Journal article
A rapid, direct test for zidovudine susceptibility in clinical isolates of human immunodeficiency virus type 1 (HIV-1) from infected children
Clinical and diagnostic virology, v 3(3), pp 259-271
1995
PMID: 15566807
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Abstract
Existing phenotypic tests of antiretroviral susceptibility in clinical isolates of human immunodeficiency virus (HIV) are expensive and slow, and require passage of virus in cell culture with the possible consequence of selecting variants.
We sought to develop a rapid 14-day assay for zidovudine susceptibility of cell-associated HIV performed directly in patient blood samples.
Twenty-three tests were performed prospectively in 21 children, and the results were compared with those of the AIDS Clinical Trials Group/Department of Defense consensus drug susceptibility assay (DSA) as well as certain clinical parameters.
Five strains from ZDV-naive children were sensitive by the rapid test. Three were tested by DSA, and all were sensitive. Six strains from children who had received ≥24 months of ZDV were resistant by the rapid assay. Four of these strains were tested by the DSA, and all were shown resistant. The viral strains from children who received <24 months of therapy or who had switched from ZDV to other antiviral therapy exhibited variable sensitivity by both tests. Changes in CD4 cells in the subsequent 6 months, as well as weight gain during this time were both correlated to the results of the rapid test. The syncytium-inducing capacity of the virus strains was analyzed similarly.
The rapid intracellular virus susceptibility assay is a test of drug sensitivity performed on HIV growing in cells obtained directly from an infected patient. The test has a two-week turn-around time and, in this preliminary report, gives results which correlate with both time on zidovudine and also subsequent CD4 cell changes.
Metrics
Details
- Title
- A rapid, direct test for zidovudine susceptibility in clinical isolates of human immunodeficiency virus type 1 (HIV-1) from infected children
- Creators
- Yan Lan - Division of Infectious Diseases, Children's Hospital, 300 Longwood Avenue, Boston, MA 02115, USAAnthony J Japour - Division of Infectious Diseases, Beth Israel Hospital, Departments of Pediatrics and Medicine, Harvard Medical School, Boston, MA, USASteven Kim - Division of Infectious Diseases, Beth Israel Hospital, Departments of Pediatrics and Medicine, Harvard Medical School, Boston, MA, USASeth L Welles - Statistical Data Analysis Center, Department of Biostatistics, Harvard School of Public Health, Boston, MA, USAClyde S Crumpacker - Division of Infectious Diseases, Beth Israel Hospital, Departments of Pediatrics and Medicine, Harvard Medical School, Boston, MA, USAEllen Cooper - Department of Pediatric Infectious Diseases, Boston City Hospital, and Department of Pediatrics, Boston University, Boston, MA, USAInas Al-Attar - Division of Infectious Diseases, Children's Hospital, 300 Longwood Avenue, Boston, MA 02115, USAKenneth McIntosh - Division of Infectious Diseases, Children's Hospital, 300 Longwood Avenue, Boston, MA 02115, USA
- Publication Details
- Clinical and diagnostic virology, v 3(3), pp 259-271
- Publisher
- Elsevier
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Epidemiology and Biostatistics
- Web of Science ID
- WOS:A1995QN55700006
- Scopus ID
- 2-s2.0-0028958126
- Other Identifier
- 991014878607104721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
Source: SDGs in the Output
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Virology